C92.0
Acute myeloblastic leukemia
Clinical Classification Guidelines
Inclusion Terms
- Acute myeloblastic leukemia, minimal differentiation
- Acute myeloblastic leukemia (with maturation)
- Acute myeloblastic leukemia 1/ETO
- Acute myeloblastic leukemia M0
- Acute myeloblastic leukemia M1
- Acute myeloblastic leukemia M2
- Acute myeloblastic leukemia with t(8;21)
- Acute myeloblastic leukemia (without a FAB classification) NOS
- Refractory anemia with excess blasts in transformation [RAEB T]
Excludes Type 1
- acute exacerbation of chronic myeloid leukemia (C92.10)
- refractory anemia with excess of blasts not in transformation (D46.2-)
Medical Intelligence & Overview
Acute myeloblastic leukemia (AML) is a fast-growing cancer of the blood and bone marrow, characterized by the rapid proliferation of abnormal myeloid cells. This disease causes the bone marrow to produce immature white blood cells, known as myeloblasts, which can interfere with normal blood cell functions. AML primarily affects adults and requires prompt medical attention due to its aggressive nature. Recognized under ICD-10 code C92.0, AML encompasses different subtypes based on specific genetic features and the degree of cell differentiation.
Causes & Symptoms
Clinical Causes: Genetic mutations: Changes in chromosomes or specific genes may initiate abnormal cell growth. Previous chemotherapy or radiation therapy: Past cancer treatments can increase risk. Exposure to certain chemicals: Such as benzene or other industrial toxins. Hereditary conditions: Certain genetic syndromes may predispose individuals. Age: Risk increases significantly with advancing age, especially in adults over 60. Lifestyle factors: Smoking and exposure to environmental hazards may also contribute.
Key Symptoms: Frequent infections due to compromised immune function Unusual bleeding or bruising easily Pale skin or anemia, leading to fatigue Shortness of breath or dizziness Fever and night sweats Bone or joint pain Weakness or exhaustion Swollen lymph nodes or spleen
Diagnostic & Treatment
Diagnosis Path: Diagnosing AML involves several tests to confirm the presence and subtype of leukemia:
Treatment Protocols: AML treatment aims to eliminate leukemia cells and restore normal blood function, often involving multiple strategies:
Clinical Advice & FAQs
Billing Guidance
Is C92.0 a billable ICD-10 code?
Yes, C92.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.0?
Clinical documentation must specify the nature of Acute myeloblastic leukemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference